<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">37333243</PMID><DateRevised><Year>2024</Year><Month>09</Month><Day>23</Day></DateRevised><Article PubModel="Electronic"><Journal><JournalIssue CitedMedium="Internet"><PubDate><Year>2023</Year><Month>Jun</Month><Day>07</Day></PubDate></JournalIssue><Title>medRxiv : the preprint server for health sciences</Title><ISOAbbreviation>medRxiv</ISOAbbreviation></Journal><ArticleTitle>Metformin reduces SARS-CoV-2 in a Phase 3 Randomized Placebo Controlled Clinical Trial.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">2023.06.06.23290989</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1101/2023.06.06.23290989</ELocationID><Abstract><AbstractText>Current antiviral treatment options for SARS-CoV-2 infections are not available globally, cannot be used with many medications, and are limited to virus-specific targets.<sup>1-3</sup> Biophysical modeling of SARS-CoV-2 replication predicted that protein translation is an especially attractive target for antiviral therapy.<sup>4</sup> Literature review identified metformin, widely known as a treatment for diabetes, as a potential suppressor of protein translation via targeting of the host mTor pathway.<sup>5</sup> In vitro, metformin has antiviral activity against RNA viruses including SARS-CoV-2.<sup>6,7</sup> In the COVID-OUT phase 3, randomized, placebo-controlled trial of outpatient treatment of COVID-19, metformin had a 42% reduction in ER visits/hospitalizations/death through 14 days; a 58% reduction in hospitalizations/death through 28 days, and a 42% reduction in Long COVID through 10 months.<sup>8,9</sup> Here we show viral load analysis of specimens collected in the COVID-OUT trial that the mean SARS-CoV-2 viral load was reduced 3.6-fold with metformin relative to placebo (-0.56 log<sub>10</sub> copies/mL; 95%CI, -1.05 to -0.06, p=0.027) while there was no virologic effect for ivermectin or fluvoxamine vs placebo. The metformin effect was consistent across subgroups and with emerging data.<sup>10,11</sup> Our results demonstrate, consistent with model predictions, that a safe, widely available,<sup>12</sup> well-tolerated, and inexpensive oral medication, metformin, can be repurposed to significantly reduce SARS-CoV-2 viral load.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Bramante</LastName><ForeName>Carolyn T</ForeName><Initials>CT</Initials><AffiliationInfo><Affiliation>General Internal Medicine, University of Minnesota, Minneapolis, MN.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Beckman</LastName><ForeName>Kenneth B</ForeName><Initials>KB</Initials><AffiliationInfo><Affiliation>Genomics Center, University of Minnesota, Minneapolis, MN.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mehta</LastName><ForeName>Tanvi</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Division of Biostatistics, School of Public Health, University of Minnesota, Minneapolis, MN.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Karger</LastName><ForeName>Amy B</ForeName><Initials>AB</Initials><AffiliationInfo><Affiliation>Department of Laboratory Medicine and Pathology, Medical School, University of Minnesota, Minneapolis, MN.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Odde</LastName><ForeName>David J</ForeName><Initials>DJ</Initials><AffiliationInfo><Affiliation>Department of Biomedical Engineering University of Minnesota, Minneapolis, MN.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tignanelli</LastName><ForeName>Christopher J</ForeName><Initials>CJ</Initials><AffiliationInfo><Affiliation>Department of Surgery, Medical School, University of Minnesota, Minneapolis, MN.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Buse</LastName><ForeName>John B</ForeName><Initials>JB</Initials><AffiliationInfo><Affiliation>Endocrinology, University of North Carolina, Chapel Hill, NC.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Johnson</LastName><ForeName>Darrell M</ForeName><Initials>DM</Initials><AffiliationInfo><Affiliation>Genomics Center, University of Minnesota, Minneapolis, MN.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Watson</LastName><ForeName>Ray H B</ForeName><Initials>RHB</Initials><AffiliationInfo><Affiliation>Genomics Center, University of Minnesota, Minneapolis, MN.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Daniel</LastName><ForeName>Jerry J</ForeName><Initials>JJ</Initials><AffiliationInfo><Affiliation>Genomics Center, University of Minnesota, Minneapolis, MN.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liebovitz</LastName><ForeName>David M</ForeName><Initials>DM</Initials><AffiliationInfo><Affiliation>General Internal Medicine, Northwestern University, Chicago, IL.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nicklas</LastName><ForeName>Jacinda M</ForeName><Initials>JM</Initials><AffiliationInfo><Affiliation>General Internal Medicine, University of Colorado, Denver, CO.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cohen</LastName><ForeName>Kenneth</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>UnitedHealth Group, Optum Labs, Minnetonka, MN.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Puskarich</LastName><ForeName>Michael A</ForeName><Initials>MA</Initials><AffiliationInfo><Affiliation>Emergency Medicine, Hennepin County Medical Center, Minneapolis, MN.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Belani</LastName><ForeName>Hrishikesh K</ForeName><Initials>HK</Initials><AffiliationInfo><Affiliation>Department of Medicine, Olive View - University of California, Los Angeles, CA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Siegel</LastName><ForeName>Lianne K</ForeName><Initials>LK</Initials><AffiliationInfo><Affiliation>Division of Biostatistics, School of Public Health, University of Minnesota, Minneapolis, MN.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Klatt</LastName><ForeName>Nichole R</ForeName><Initials>NR</Initials><AffiliationInfo><Affiliation>Department of Surgery, Medical School, University of Minnesota, Minneapolis, MN.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Anderson</LastName><ForeName>Blake</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Atlanta Veterans Affairs Medical Center, Atlanta, Georgia; Department of Medicine, Emory University School of Medicine, Atlanta, GA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hartman</LastName><ForeName>Katrina M</ForeName><Initials>KM</Initials><AffiliationInfo><Affiliation>General Internal Medicine, University of Minnesota, Minneapolis, MN.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rao</LastName><ForeName>Via</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>General Internal Medicine, University of Minnesota, Minneapolis, MN.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hagen</LastName><ForeName>Aubrey A</ForeName><Initials>AA</Initials><AffiliationInfo><Affiliation>General Internal Medicine, University of Minnesota, Minneapolis, MN.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Patel</LastName><ForeName>Barkha</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>General Internal Medicine, University of Minnesota, Minneapolis, MN.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fenno</LastName><ForeName>Sarah L</ForeName><Initials>SL</Initials><AffiliationInfo><Affiliation>General Internal Medicine, University of Minnesota, Minneapolis, MN.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Avula</LastName><ForeName>Nandini</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>General Internal Medicine, University of Minnesota, Minneapolis, MN.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Reddy</LastName><ForeName>Neha V</ForeName><Initials>NV</Initials><AffiliationInfo><Affiliation>General Internal Medicine, University of Minnesota, Minneapolis, MN.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Erickson</LastName><ForeName>Spencer M</ForeName><Initials>SM</Initials><AffiliationInfo><Affiliation>General Internal Medicine, University of Minnesota, Minneapolis, MN.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fricton</LastName><ForeName>Regina D</ForeName><Initials>RD</Initials><AffiliationInfo><Affiliation>General Internal Medicine, Northwestern University, Chicago, IL.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lee</LastName><ForeName>Samuel</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>General Internal Medicine, Northwestern University, Chicago, IL.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Griffiths</LastName><ForeName>Gwendolyn</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>General Internal Medicine, University of Minnesota, Minneapolis, MN.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pullen</LastName><ForeName>Matthew F</ForeName><Initials>MF</Initials><AffiliationInfo><Affiliation>Division of Infectious Diseases and International Medicine, University of Minnesota, Minneapolis, MN.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Thompson</LastName><ForeName>Jennifer L</ForeName><Initials>JL</Initials><AffiliationInfo><Affiliation>Department of Obstetrics and Gynecology, Vanderbilt University Medical Center, Nashville, TN.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sherwood</LastName><ForeName>Nancy</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Division of Epidemiology and Community Health, School of Public Health, University of Minnesota, Minneapolis, MN.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Murray</LastName><ForeName>Thomas A</ForeName><Initials>TA</Initials><AffiliationInfo><Affiliation>Division of Biostatistics, School of Public Health, University of Minnesota, Minneapolis, MN.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rose</LastName><ForeName>Michael R</ForeName><Initials>MR</Initials><AffiliationInfo><Affiliation>Division of Epidemiology and Community Health, School of Public Health, University of Minnesota, Minneapolis, MN.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Boulware</LastName><ForeName>David R</ForeName><Initials>DR</Initials><AffiliationInfo><Affiliation>Division of Infectious Diseases and International Medicine, University of Minnesota, Minneapolis, MN.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Huling</LastName><ForeName>Jared D</ForeName><Initials>JD</Initials><AffiliationInfo><Affiliation>Division of Biostatistics, School of Public Health, University of Minnesota, Minneapolis, MN.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>P30 DK048520</GrantID><Acronym>DK</Acronym><Agency>NIDDK NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR002494</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>OT2 HL161847</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR002489</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U54 CA210190</GrantID><Acronym>CA</Acronym><Agency>NCI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>T32 HL129956</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 DK124723</GrantID><Acronym>DK</Acronym><Agency>NIDDK NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R21 LM012744</GrantID><Acronym>LM</Acronym><Agency>NLM NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>OT2 HL156812</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>INV-017069</GrantID><Acronym>GATES</Acronym><Agency>Bill &amp; Melinda Gates Foundation</Agency><Country>United States</Country></Grant><Grant><GrantID>K23 DK124654</GrantID><Acronym>DK</Acronym><Agency>NIDDK NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 LM012982</GrantID><Acronym>LM</Acronym><Agency>NLM NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K23 HL133604</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>KL2 TR002492</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01 CA254849</GrantID><Acronym>CA</Acronym><Agency>NCI NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D000076942">Preprint</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>06</Month><Day>07</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>medRxiv</MedlineTA><NlmUniqueID>101767986</NlmUniqueID></MedlineJournalInfo></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>6</Month><Day>19</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>6</Month><Day>19</Day><Hour>6</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>6</Month><Day>19</Day><Hour>2</Hour><Minute>47</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2023</Year><Month>6</Month><Day>16</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37333243</ArticleId><ArticleId IdType="pmc">PMC10275003</ArticleId><ArticleId IdType="doi">10.1101/2023.06.06.23290989</ArticleId><ArticleId IdType="pii">2023.06.06.23290989</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Bramante CT, Huling JD, Tignanelli CJ, et al. Randomized Trial of Metformin, Ivermectin, and Fluvoxamine for Covid-19. The New England journal of medicine. Aug 18 2022;387(7):599&#x2013;610. doi: 10.1056/NEJMoa2201662</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2201662</ArticleId><ArticleId IdType="pmc">PMC9945922</ArticleId><ArticleId IdType="pubmed">36070710</ArticleId></ArticleIdList></Reference><Reference><Citation>Bramante C.T.
B J.B., Liebovitz D.
et al.
Outpatient Treatment of Covid-19 and the Development of Long Covid over 10 Months: A Multi-Center, Quadruple-Blind, Parallel Group Randomized Phase 3 Trial. https://ssrncom/abstract=4375620
2023;</Citation><ArticleIdList><ArticleId IdType="pmc">PMC11259948</ArticleId><ArticleId IdType="pubmed">37302406</ArticleId></ArticleIdList></Reference><Reference><Citation>Castle BT, Dock C, Hemmat M, et al. Biophysical modeling of the SARS-CoV-2 viral cycle reveals ideal antiviral targets. bioRxiv. 2020:2020.05.22.111237. doi:10.1101/2020.05.22.111237</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2020.05.22.111237</ArticleId></ArticleIdList></Reference><Reference><Citation>Gordon DE, Jang GM, Bouhaddou M, et al. A SARS-CoV-2 protein interaction map reveals targets for drug repurposing. Nature. Jul 2020;583(7816):459&#x2013;468. doi:10.1038/s41586-020-2286-9</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-020-2286-9</ArticleId><ArticleId IdType="pmc">PMC7431030</ArticleId><ArticleId IdType="pubmed">32353859</ArticleId></ArticleIdList></Reference><Reference><Citation>Schaller MA, Sharma Y, Dupee Z, et al. Ex vivo SARS-CoV-2 infection of human lung reveals heterogeneous host defense and therapeutic responses. JCI Insight. Sep 22 2021;6(18)doi:10.1172/jci.insight.148003</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/jci.insight.148003</ArticleId><ArticleId IdType="pmc">PMC8492301</ArticleId><ArticleId IdType="pubmed">34357881</ArticleId></ArticleIdList></Reference><Reference><Citation>Howell JJ, Hellberg K, Turner M, et al. Metformin Inhibits Hepatic mTORC1 Signaling via Dose-Dependent Mechanisms Involving AMPK and the TSC Complex. Cell Metab. Feb 7 2017;25(2):463&#x2013;471. doi:10.1016/j.cmet.2016.12.009</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cmet.2016.12.009</ArticleId><ArticleId IdType="pmc">PMC5299044</ArticleId><ArticleId IdType="pubmed">28089566</ArticleId></ArticleIdList></Reference><Reference><Citation>Bailey CJ. Metformin: historical overview. Diabetologia. Sep 2017;60(9):1566&#x2013;1576. doi:10.1007/s00125-017-4318-z</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00125-017-4318-z</ArticleId><ArticleId IdType="pubmed">28776081</ArticleId></ArticleIdList></Reference><Reference><Citation>EY G. Flumamine, a new synthetic analgesic and antiflu drug. Philippine Med Assoc. 1950;26:287&#x2013;293.</Citation><ArticleIdList><ArticleId IdType="pubmed">14779282</ArticleId></ArticleIdList></Reference><Reference><Citation>Singh S, Singh PK, Suhail H, et al. AMP-Activated Protein Kinase Restricts Zika Virus Replication in Endothelial Cells by Potentiating Innate Antiviral Responses and Inhibiting Glycolysis. J Immunol. Apr 1 2020;204(7):1810&#x2013;1824. doi:10.4049/jimmunol.1901310</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.1901310</ArticleId><ArticleId IdType="pmc">PMC7310572</ArticleId><ArticleId IdType="pubmed">32086387</ArticleId></ArticleIdList></Reference><Reference><Citation>Cheng F, Ramos da Silva S, Huang IC, Jung JU, Gao SJ. Suppression of Zika Virus Infection and Replication in Endothelial Cells and Astrocytes by PKA Inhibitor PKI 14-22. J Virol. Feb 15 2018;92(4):e02019&#x2013;17. doi:10.1128/JVI.02019-17</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.02019-17</ArticleId><ArticleId IdType="pmc">PMC5790943</ArticleId><ArticleId IdType="pubmed">29212931</ArticleId></ArticleIdList></Reference><Reference><Citation>Del Campo JA, Garc&#xed;a-Valdecasas M, Gil-G&#xf3;mez A, et al. Simvastatin and metformin inhibit cell growth in hepatitis C virus infected cells via mTOR increasing PTEN and autophagy. PloS one. 2018;13(1):e0191805. doi:10.1371/journal.pone.0191805</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0191805</ArticleId><ArticleId IdType="pmc">PMC5791999</ArticleId><ArticleId IdType="pubmed">29385181</ArticleId></ArticleIdList></Reference><Reference><Citation>Maiese K. The Mechanistic Target of Rapamycin (mTOR): Novel Considerations as an Antiviral Treatment. Curr Neurovasc Res. Apr 25 2020; doi:10.2174/1567202617666200425205122</Citation><ArticleIdList><ArticleId IdType="doi">10.2174/1567202617666200425205122</ArticleId><ArticleId IdType="pmc">PMC7541431</ArticleId><ArticleId IdType="pubmed">32334502</ArticleId></ArticleIdList></Reference><Reference><Citation>Greenland S, Mansournia MA, Altman DG. Sparse data bias: a problem hiding in plain sight. BMJ (Clinical research ed). Apr 27 2016;352:i1981. doi:10.1136/bmj.i1981</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.i1981</ArticleId><ArticleId IdType="pubmed">27121591</ArticleId></ArticleIdList></Reference><Reference><Citation>Ventura-L&#xf3;pez C, Cervantes-Luevano K, Aguirre-S&#xe1;nchez JS, et al. Treatment with metformin glycinate reduces SARS-CoV-2 viral load: An in vitro model and randomized, double-blind, Phase IIb clinical trial. Biomed Pharmacother. Aug 2022; 152:113223. doi:10.1016/j.biopha.2022.113223</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.biopha.2022.113223</ArticleId><ArticleId IdType="pmc">PMC9159967</ArticleId><ArticleId IdType="pubmed">35709650</ArticleId></ArticleIdList></Reference><Reference><Citation>Parthasarathy H, Tandel D, Siddiqui AH, Harshan KH. Metformin suppresses SARS-CoV-2 in cell culture. Virus Res. Nov 20 2022;323:199010. doi:10.1016/j.virusres.2022.199010</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.virusres.2022.199010</ArticleId><ArticleId IdType="pmc">PMC9676078</ArticleId><ArticleId IdType="pubmed">36417940</ArticleId></ArticleIdList></Reference><Reference><Citation>Rodrigues TS, de S&#xe1; KSG, Ishimoto AY, et al. Inflammasomes are activated in response to SARS-CoV-2 infection and are associated with COVID-19 severity in patients. J Exp Med. Mar 1 2021;218(3)doi:10.1084/jem.20201707</Citation><ArticleIdList><ArticleId IdType="doi">10.1084/jem.20201707</ArticleId><ArticleId IdType="pmc">PMC7684031</ArticleId><ArticleId IdType="pubmed">33231615</ArticleId></ArticleIdList></Reference><Reference><Citation>Hyun B, Shin S, Lee A, et al. Metformin Down-regulates TNF-&#x3b1; Secretion via Suppression of Scavenger Receptors in Macrophages. Immune Netw. Aug 2013;13(4):123&#x2013;32. doi:10.4110/in.2013.13.4.123</Citation><ArticleIdList><ArticleId IdType="doi">10.4110/in.2013.13.4.123</ArticleId><ArticleId IdType="pmc">PMC3759709</ArticleId><ArticleId IdType="pubmed">24009539</ArticleId></ArticleIdList></Reference><Reference><Citation>Buse JB, DeFronzo RA, Rosenstock J, et al. The Primary Glucose-Lowering Effect of Metformin Resides in the Gut, Not the Circulation: Results From Short-term Pharmacokinetic and 12-Week Dose-Ranging Studies. Diabetes care. Feb 2016;39(2):198&#x2013;205. doi:10.2337/dc15-0488</Citation><ArticleIdList><ArticleId IdType="doi">10.2337/dc15-0488</ArticleId><ArticleId IdType="pubmed">26285584</ArticleId></ArticleIdList></Reference><Reference><Citation>Hammond J, Leister-Tebbe H, Gardner A, et al. Oral Nirmatrelvir for High-Risk, Nonhospitalized Adults with Covid-19. The New England journal of medicine. Apr 14 2022;386(15): 1397&#x2013;1408. doi:10.1056/NEJMoa2118542</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2118542</ArticleId><ArticleId IdType="pmc">PMC8908851</ArticleId><ArticleId IdType="pubmed">35172054</ArticleId></ArticleIdList></Reference><Reference><Citation>Jayk Bernal A, Gomes da Silva MM, Musungaie DB, et al. Molnupiravir for Oral Treatment of Covid-19 in Nonhospitalized Patients. New England Journal of Medicine. 2022/02/10 2021;386(6):509&#x2013;520. doi:10.1056/NEJMoa2116044</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2116044</ArticleId><ArticleId IdType="pmc">PMC8693688</ArticleId><ArticleId IdType="pubmed">34914868</ArticleId></ArticleIdList></Reference><Reference><Citation>Maiese K. The Mechanistic Target of Rapamycin (mTOR): Novel Considerations as an Antiviral Treatment. Curr Neurovasc Res. 2020;17(3):332&#x2013;337. doi:10.2174/1567202617666200425205122</Citation><ArticleIdList><ArticleId IdType="doi">10.2174/1567202617666200425205122</ArticleId><ArticleId IdType="pmc">PMC7541431</ArticleId><ArticleId IdType="pubmed">32334502</ArticleId></ArticleIdList></Reference><Reference><Citation>P&#xe9;rez-P&#xe9;rez M-J, Saiz J-C, Priego E-M, Mart&#xed;n-Acebes MA. Antivirals against (Re)emerging Flaviviruses: Should We Target the Virus or the Host? ACS Medicinal Chemistry Letters. 2022/01/13 2022;13(1):5&#x2013;10. doi:10.1021/acsmedchemlett.1c00617</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acsmedchemlett.1c00617</ArticleId><ArticleId IdType="pmc">PMC8762743</ArticleId><ArticleId IdType="pubmed">35059112</ArticleId></ArticleIdList></Reference><Reference><Citation>Xian H, Liu Y, Rundberg Nilsson A, et al. Metformin inhibition of mitochondrial ATP and DNA synthesis abrogates NLRP3 inflammasome activation and pulmonary inflammation. Immunity. Jul 13 2021;54(7):1463&#x2013;1477.e11. doi:10.1016/j.immuni.2021.05.004</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.immuni.2021.05.004</ArticleId><ArticleId IdType="pmc">PMC8189765</ArticleId><ArticleId IdType="pubmed">34115964</ArticleId></ArticleIdList></Reference><Reference><Citation>Barnette KG, Gordon Michael S, Rodriguez D, et al. Oral Sabizabulin for High-Risk, Hospitalized Adults with Covid-19: Interim Analysis. NEJM Evidence. 2022/08/23 2022;1(9):EVIDoa2200145. doi:10.1056/EVIDoa2200145</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/EVIDoa2200145</ArticleId><ArticleId IdType="pubmed">38319812</ArticleId></ArticleIdList></Reference><Reference><Citation>Bramante CT, Proper JL, Boulware DR, et al. Vaccination Against SARS-CoV-2 Is Associated With a Lower Viral Load and Likelihood of Systemic Symptoms. Open Forum Infectious Diseases. 2022;9(5):ofac066. doi:10.1093/ofid/ofac066</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ofid/ofac066</ArticleId><ArticleId IdType="pmc">PMC8982774</ArticleId><ArticleId IdType="pubmed">35392460</ArticleId></ArticleIdList></Reference><Reference><Citation>Jayk Bernal A, Gomes da Silva MM, Musungaie DB, et al. Molnupiravir for Oral Treatment of Covid-19 in Nonhospitalized Patients. The New England journal of medicine. Feb 10 2022;386(6):509&#x2013;520. doi:10.1056/NEJMoa2116044</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2116044</ArticleId><ArticleId IdType="pmc">PMC8693688</ArticleId><ArticleId IdType="pubmed">34914868</ArticleId></ArticleIdList></Reference><Reference><Citation>Goto M, Perencevich EN. Metformin and Infections: What Is the Next Step in This Decades-Long Story? Clinical Infectious Diseases. 2023;76(7):1245&#x2013;1246. doi:10.1093/cid/ciac903</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cid/ciac903</ArticleId><ArticleId IdType="pubmed">36560871</ArticleId></ArticleIdList></Reference><Reference><Citation>Mohammed T, Bowe M, Plant A, Perez M, Alvarez CA, Mortensen EM. Metformin Use Is Associated With Lower Mortality in Veterans With Diabetes Hospitalized With Pneumonia. Clin Infect Dis. Apr 3 2023;76(7):1237&#x2013;1244. doi:10.1093/cid/ciac900</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cid/ciac900</ArticleId><ArticleId IdType="pmc">PMC10319762</ArticleId><ArticleId IdType="pubmed">36575139</ArticleId></ArticleIdList></Reference><Reference><Citation>Yu J-W, Sun L-J, Zhao Y-H, Kang P, Yan B-Z. The effect of metformin on the efficacy of antiviral therapy in patients with genotype 1 chronic hepatitis C and insulin resistance. International Journal of Infectious Diseases. 2012;16(6):e436&#x2013;e441. doi:10.1016/j.ijid.2012.02.004</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijid.2012.02.004</ArticleId><ArticleId IdType="pubmed">22486858</ArticleId></ArticleIdList></Reference><Reference><Citation>Wabitsch S, McCallen JD, Kamenyeva O, et al. Metformin treatment rescues CD8+ T-cell response to immune checkpoint inhibitor therapy in mice with NAFLD. Journal of Hepatology. 2022/09/01/ 2022;77(3):748&#x2013;760. doi:10.1016/j.jhep.2022.03.010</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jhep.2022.03.010</ArticleId><ArticleId IdType="pmc">PMC9391315</ArticleId><ArticleId IdType="pubmed">35378172</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu L, Wang X, Chen Y, et al. Metformin Modulates T Cell Function and Alleviates Liver Injury Through Bioenergetic Regulation in Viral Hepatitis. Original Research. Frontiers in Immunology. 2021-April-21 2021 ;12doi:10.3389/fimmu.2021.638575</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2021.638575</ArticleId><ArticleId IdType="pmc">PMC8097169</ArticleId><ArticleId IdType="pubmed">33968030</ArticleId></ArticleIdList></Reference><Reference><Citation>Henry RR, Frias JP, Walsh B, et al. Improved glycemic control with minimal systemic metformin exposure: Effects of Metformin Delayed-Release (Metformin DR) targeting the lower bowel over 16 weeks in a randomized trial in subjects with type 2 diabetes. PloS one. 2018;13(9):e0203946. doi:10.1371/journal.pone.0203946</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0203946</ArticleId><ArticleId IdType="pmc">PMC6155522</ArticleId><ArticleId IdType="pubmed">30252913</ArticleId></ArticleIdList></Reference><Reference><Citation>Iketani S, Mohri H, Culbertson B, et al. Multiple pathways for SARS-CoV-2 resistance to nirmatrelvir. Nature. Nov 9 2022;doi:10.1038/s41586-022-05514-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-022-05514-2</ArticleId><ArticleId IdType="pmc">PMC9849135</ArticleId><ArticleId IdType="pubmed">36351451</ArticleId></ArticleIdList></Reference><Reference><Citation>WHO. Therapeutics and COVID-19. 2022;</Citation></Reference><Reference><Citation>Pepperrell T, Ellis L, Wang J, Hill A. Barriers to Worldwide Access for Paxlovid, a New Treatment for COVID-19. Open Forum Infectious Diseases. 2022;9(9):ofac174.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9383702</ArticleId><ArticleId IdType="pubmed">36176569</ArticleId></ArticleIdList></Reference><Reference><Citation>Castle BT, Dock C, Hemmat M, et al. Biophysical modeling of the SARS-CoV-2 viral cycle reveals ideal antiviral targets. bioRxiv. 2020:2020.05.22.111237. doi:10.1101/2020.05.22.111237</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2020.05.22.111237</ArticleId></ArticleIdList></Reference><Reference><Citation>Howell JJ, Hellberg K, Turner M, et al. Metformin Inhibits Hepatic mTORC1 Signaling via Dose-Dependent Mechanisms Involving AMPK and the TSC Complex. Cell Metab. Feb 7 2017;25(2):463&#x2013;471. doi:10.1016/j.cmet.2016.12.009</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cmet.2016.12.009</ArticleId><ArticleId IdType="pmc">PMC5299044</ArticleId><ArticleId IdType="pubmed">28089566</ArticleId></ArticleIdList></Reference><Reference><Citation>Gordon DE, Jang GM, Bouhaddou M, et al. A SARS-CoV-2 protein interaction map reveals targets for drug repurposing. Nature. 2020/07/01 2020;583(7816):459&#x2013;468. doi:10.1038/s41586-020-2286-9</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-020-2286-9</ArticleId><ArticleId IdType="pmc">PMC7431030</ArticleId><ArticleId IdType="pubmed">32353859</ArticleId></ArticleIdList></Reference><Reference><Citation>Singh S, Singh PK, Suhail H, et al. AMP-Activated Protein Kinase Restricts Zika Virus Replication in Endothelial Cells by Potentiating Innate Antiviral Responses and Inhibiting Glycolysis. J Immunol. Apr 1 2020;204(7):1810&#x2013;1824. doi:10.4049/jimmunol.1901310</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.1901310</ArticleId><ArticleId IdType="pmc">PMC7310572</ArticleId><ArticleId IdType="pubmed">32086387</ArticleId></ArticleIdList></Reference><Reference><Citation>Bramante CT, Huling JD, Tignanelli CJ, et al. Randomized Trial of Metformin, Ivermectin, and Fluvoxamine for Covid-19. The New England journal of medicine. Aug 18 2022;387(7):599&#x2013;610. doi:10.1056/NEJMoa2201662</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2201662</ArticleId><ArticleId IdType="pmc">PMC9945922</ArticleId><ArticleId IdType="pubmed">36070710</ArticleId></ArticleIdList></Reference><Reference><Citation>Bramante CT, Buse JB, Liebovitz DM, et al.
Outpatient treatment of Covid-19 and the development of Long Covid over 10 months: A multi-center, quadruple-blind, parallel group randomized phase 3 trial. 2023;In press:https://papers.ssrn.com/sol3/papers.cfm?abstract_id=4375620.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC11259948</ArticleId><ArticleId IdType="pubmed">37302406</ArticleId></ArticleIdList></Reference><Reference><Citation>Ventura-L&#xf3;pez C, Cervantes-Luevano K, Aguirre-S&#xe1;nchez JS, et al. Treatment with metformin glycinate reduces SARS-CoV-2 viral load: An in vitro model and randomized, double-blind, Phase IIb clinical trial. Biomed Pharmacother. Aug 2022;152:113223. doi:10.1016/j.biopha.2022.113223</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.biopha.2022.113223</ArticleId><ArticleId IdType="pmc">PMC9159967</ArticleId><ArticleId IdType="pubmed">35709650</ArticleId></ArticleIdList></Reference><Reference><Citation>Parthasarathy H, Tandel D, Siddiqui AH, Harshan KH. Metformin suppresses SARS-CoV-2 in cell culture. Virus Res. Nov 20 2022;323:199010. doi:10.1016/j.virusres.2022.199010</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.virusres.2022.199010</ArticleId><ArticleId IdType="pmc">PMC9676078</ArticleId><ArticleId IdType="pubmed">36417940</ArticleId></ArticleIdList></Reference><Reference><Citation>Shenoy S. SARS-CoV-2 (COVID-19), viral load and clinical outcomes; lessons learned one year into the pandemic: A systematic review. World J Crit Care Med. Jul 9 2021;10(4):132&#x2013;150. doi:10.5492/wjccm.v10.i4.132</Citation><ArticleIdList><ArticleId IdType="doi">10.5492/wjccm.v10.i4.132</ArticleId><ArticleId IdType="pmc">PMC8291003</ArticleId><ArticleId IdType="pubmed">34316448</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>